These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 22162534)

  • 21. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.
    Chamberlain SR; Mogg K; Bradley BP; Koch A; Dodds CM; Tao WX; Maltby K; Sarai B; Napolitano A; Richards DB; Bullmore ET; Nathan PJ
    Psychopharmacology (Berl); 2012 Dec; 224(4):501-9. PubMed ID: 22752384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
    Russell T; Stoltz M; Weir S
    Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.
    Chen D; Whitcomb R; MacIntyre E; Tran V; Do ZN; Sabry J; Patel DV; Anandan SK; Gless R; Webb HK
    J Clin Pharmacol; 2012 Mar; 52(3):319-28. PubMed ID: 21422238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
    LaForce C; Alexander M; Deckelmann R; Fabbri LM; Aisanov Z; Cameron R; Owen R; Higgins M
    Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.
    Katz LB; Gambale JJ; Rothenberg PL; Vanapalli SR; Vaccaro N; Xi L; Sarich TC; Stein PP
    Diabetes Obes Metab; 2012 Aug; 14(8):709-16. PubMed ID: 22340428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
    Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
    Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study.
    Kanniess F; Boulet LP; Pierzchala W; Cameron R; Owen R; Higgins M
    J Asthma; 2008 Dec; 45(10):887-92. PubMed ID: 19085578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2.
    Bain G; King CD; Brittain J; Hartung JP; Dearmond I; Stearns B; Truong YP; Hutchinson JH; Evans JF; Holme K
    J Clin Pharmacol; 2012 Oct; 52(10):1482-93. PubMed ID: 22110163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers.
    Soergel DG; Subach RA; Sadler B; Connell J; Marion AS; Cowan CL; Violin JD; Lark MW
    J Clin Pharmacol; 2014 Mar; 54(3):351-7. PubMed ID: 24122908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.
    Cambridge VC; Ziauddeen H; Nathan PJ; Subramaniam N; Dodds C; Chamberlain SR; Koch A; Maltby K; Skeggs AL; Napolitano A; Farooqi IS; Bullmore ET; Fletcher PC
    Biol Psychiatry; 2013 May; 73(9):887-94. PubMed ID: 23245760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in Psychopharmacology 232, 305-314, 2014.
    Wang D; Sadee W
    Psychopharmacology (Berl); 2015 Apr; 232(8):1493-4. PubMed ID: 25740344
    [No Abstract]   [Full Text] [Related]  

  • 35. Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.
    Nathan PJ; Bakker G
    Psychopharmacology (Berl); 2021 May; 238(5):1255-1263. PubMed ID: 31900526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total-body imaging of mu-opioid receptors with [
    Hsieh CJ; Hou C; Lee H; Tomita C; Schmitz A; Plakas K; Dubroff JG; Mach RH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3273-3283. PubMed ID: 38722383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reply to Wang and Sadée.
    Henderson G; Bullmore ET
    Psychopharmacology (Berl); 2015 Apr; 232(8):1495-6. PubMed ID: 25757674
    [No Abstract]   [Full Text] [Related]  

  • 38. Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys.
    Minervini V; Disney A; Husbands SM; France CP
    Psychopharmacology (Berl); 2020 Oct; 237(10):3057-3065. PubMed ID: 32772146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
    Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
    Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of cognitive safety in clinical drug development.
    Roiser JP; Nathan PJ; Mander AP; Adusei G; Zavitz KH; Blackwell AD
    Drug Discov Today; 2016 Mar; 21(3):445-53. PubMed ID: 26610416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.